B of A Securities Maintains Buy on Minimed Group, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 43.3%

Neg 43.3% Neu 0% Pos 0%

B of A Securities analyst Travis Steed maintains Minimed Group (NASDAQ:MMED) with a Buy and lowers the price target from $27 to $20.